Article Sidebar

Submitted
12 January 2021
Accepted
12 January 2021
Published
30 September 2020
Download
PDF
Statistic
Read Counter : 636 Download : 454

Main Article Content

Abstract

The purpose of this study to describe patientscharacteristics, correlation between stagingnon-seminomacancer and chemotherapyresponse. Data on age, location of tumor, staging, serum levels of the tumor marker post operative, adjuvant therapy, chemotherapy side effects, and response of patient to chemotherapy were gained from medical records inSoetomo Hospital Surabaya from January 2012 to December 2015, and analyzed with SPSS. Correlation between staging and chemotherapyresponse, correlation primary tumor staging (pT) and Metastasis (M), correlation regional lymph nodes staging (N) and metastasis (M), correlation serum tumor marker and chemotherapy response was proccessed by Spearman correlation test. There were no significant correlation between pT staging and M and no significant correlation between N and M staging. Based on tumor markers (S), mostly patients were S2. There were no significant correlation between the response to chemotherapy and serum tumor marker levels. In category of staging group, the mostare 14 patientsstage III. BEP was the most adjuvant Chemotherapy.Nausea and vomiting were The most complained during chemotherapy. Anemia were the most hematologic side effects of chemotherapy.There are no significant correlation between the staging of non-seminoma and the response to chemotherapy. Conclusion: Non seminoma mostly happened in young males. Non-seminoma responses to chemotherapy. Patients in early stage would give a good response to chemotherapy compared to those with advanced stage. After chemotherapy, evaluation should be done to the patients' complaints and complete blood count to detect side effects.

Keywords

Germ cell tumor non-seminoma chemotherapeutic response

Article Details

License

Copyright (c) 2020 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

Author Biography

Ahmad Nugroho, Department of Urology, Faculty of Medicine, Universitas Airlangga, Dr Soetomo Hospital, Surabaya, Indonesia

Urology
How to Cite
Nugroho, A., Renaldo, J., & Djatisoesanto, W. (2020). Correlations Between Staging and Chemotheraphy Response with Testicular Carcinoma Non-Seminoma at Dr. Soetomo Hospital, Surabaya, Indonesia. Folia Medica Indonesiana, 56(3), 178–185. https://doi.org/10.20473/fmi.v56i3.24536
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Ade IM, H. S. (2015) ‘Profile of Testicular Cancer in Soetomo Hospital Surabaya'.
  2. Ahmedin Jemal. (2011) ‘Global cáncer statistic. Cancer Journal for clinician. www.', vol 61, fe. Available at: http://onlinelibrary.wiley.com.
  3. Albers, P. et al. (2014) ‘Guidelines on testicular cancer. 2014', European Association of Urology.
  4. Andrew Cramer and Mike B Siroky (2004) ‘Neoplasma of the Genitourinary Tract. Handbook of Urology :. 3rd ed', p. Lippincott williams & wilkins; Chap 15; 249 – 299.
  5. Daugaard, G. et al. (2011) ‘A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EO', Annals of Oncology. doi: 10.1093/annonc/mdq575.
  6. Daugaard, G. et al. (2014) ‘Surveillance for Stage I Nonseminoma Testicular Cancer: Outcomes and Long-Term Follow-Up in a Population-Based Cohort', Journal of Clinical Oncology. doi: 10.1200/JCO.2013.53.5831.
  7. Einhorn, L. H. (2007) ‘Role of the urologist in metastatic testicular cancer', Journal of Clinical Oncology. doi: 10.1200/JCO.2006.07.6075.
  8. Guo, J. et al. (2005) ‘Testicular cancer, occupation and exposure to chemical agents among Finnish men in 1971-1995', Cancer Causes and Control. doi: 10.1007/s10552-004-2236-0.
  9. Horwich, A., et al. (1997) ‘Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and', J Clin Oncol, 15: 1844.
  10. Houldsworth, J. et al. (2006) ‘Biology and genetics of adult male germ cell tumors', Journal of Clinical Oncology. doi: 10.1200/JCO.2006.08.4285.
  11. J.A Christian ett all. (2003) ‘Intensive induction Chemotherapy with CROP/BEP in Patient with poor prognosis Germ Cell Tumor.', Journal of clinical Oncology., p. (21) p871-877.
  12. Jerome P Richieand Graeme S steele (2012) Neoplasma of the Testis. Campbell – Walsh Urology.10 th ed. Elsevier;
  13. Joseph.J.Presti.Jr (2013) Genital Tumor. Smith's General Urology. 18thed. Lange medical book McGraw-Hill;
  14. Li, Y. X. et al. (1997) ‘Clinical characteristics, prognosis, and treatment of pelvic cryptorchid seminoma.', International journal of radiation oncology, biology, physics.
  15. Merzenich, H. et al. (2000) ‘Sorting the hype from the facts in testicular cancer: Is testicular cancer related to trauma?', Journal of Urology. doi: 10.1016/S0022-5347(05)66986-8.
  16. Motzer, R. J. et al. (2007) ‘Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.', Journal of clinical oncology : official journal of the American Society of Clinical Oncology. doi: 10.1200/JCO.2005.05.4528.
  17. Sheinfeld J., et al. (no date) ‘Management of postchemotherapy residual masses in advanced germ cell tumours.', Urol Clin North Am.
  18. Srivastava, A. and Kreiger, N. (2004) ‘Cigarette smoking and testicular cancer.', Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
  19. de Wit, R. et al. (1997) ‘Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.', Journal of clinical oncology : official journal of the American Society of Clinical Oncology. doi: 10.1200/jco.1997.15.5.1837.
  20. De Wit, R. et al. (1998) ‘Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group', British Journal of Cancer. doi: 10.1038/bjc.1998.587.